Syndax(SNDX)
搜索文档
Syndax(SNDX) - 2023 Q2 - Earnings Call Transcript
2023-08-06 09:08
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, IR Michael Metzger - CEO Neil Gallagher - President & Head, R&D Keith Goldan - CFO Peter Ordentlich - CSO Anjali Ganguli - CBO Conference Call Participants Phil Nadeau - TD Cowen Anupam Rama - JPMorgan Ashiq Mubarack - Citi Brad Canino - Stifel Michael Schmidt - Guggenheim Peter Lawson - Barclays William Wood - B. Riley Securities Justin Zelin - BTIG Operator Good ...
Syndax(SNDX) - 2023 Q2 - Quarterly Report
2023-08-04 04:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other Ju ...
Syndax(SNDX) - 2023 Q1 - Earnings Call Transcript
2023-05-09 10:53
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Madhu Kumar - Goldman Sachs Eva Privitera - TD Cowen Anupam Rama - JPMorgan Yigal Nochomovitz - Citigroup Peter Lawson - Barclays Kalpit Patel - B. Riley ...
Syndax(SNDX) - 2023 Q1 - Quarterly Report
2023-05-09 04:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...
Syndax(SNDX) - 2022 Q4 - Earnings Call Transcript
2023-03-04 04:44
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Dr. Briggs Morrison - President and Head, R&D Keith Goldan - Chief Financial Officer Dr. Peter Ordentlich - Chief Scientific Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Omari Baruti - Goldman Sachs Phil Nadeau - Cowen and Company Priyanka Grover - JPMorgan Ashiq Muba ...
Syndax(SNDX) - 2022 Q4 - Annual Report
2023-03-01 05:09
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 32-0162505 (State or Other J ...
Syndax Pharmaceuticals (SNDX) Investor Presentation - Slideshow
2023-01-28 07:54
Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 CORPORATE PRESENTATION | JANUARY 2023 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forwar ...
Syndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow
2023-01-13 00:27
Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 CORPORATE PRESENTATION | JANUARY 2023 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forwar ...